A5060713243- Renal Transplantation Outcomes and Treatments
- Organ Transplantation Techniques and Outcomes
- Liver Disease and Transplantation
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Polyomavirus and related diseases
- Renal Diseases and Glomerulopathies
- Pneumocystis jirovecii pneumonia detection and treatment
- Hepatitis Viruses Studies and Epidemiology
- Neurological Complications and Syndromes
- Transplantation: Methods and Outcomes
- Hepatitis C virus research
- Organ Donation and Transplantation
- Renal and Vascular Pathologies
- Cytomegalovirus and herpesvirus research
- Viral gastroenteritis research and epidemiology
- Pregnancy and Medication Impact
- Immune Cell Function and Interaction
- HIV/AIDS drug development and treatment
- Liver Disease Diagnosis and Treatment
- Animal Virus Infections Studies
- Blood groups and transfusion
- Hepatitis B Virus Studies
- Parathyroid Disorders and Treatments
- Hemoglobinopathies and Related Disorders
Centre Hospitalier Universitaire de Toulouse
2012-2025
Institut des Maladies Métaboliques et Cardiovasculaires
2023-2025
Hôpital Rangueil
2015-2024
Inserm
2015-2024
Centre National de la Recherche Scientifique
2021-2024
Université de Toulouse
2016-2024
Université Toulouse III - Paul Sabatier
2014-2024
Institut de Transplantation Urologie en Nephrologie
2024
Assistance Publique – Hôpitaux de Paris
2022-2024
Université Paris Cité
2024
Three Covid-19 Vaccine Doses in Transplant Recipients Solid-organ transplant recipients receiving immunosuppressive therapy appear to have a poor response vaccination. A group of 101 co...
The Banff Working Group on Liver Allograft Pathology reviewed and discussed literature evidence regarding antibody-mediated liver allograft rejection at the 11th (Paris, France, June 5-10, 2011), 12th (Comandatuba, Brazil, August 19-23, 2013), 13th (Vancouver, British Columbia, Canada, October 2015) meetings of Conference Pathology. Discussion continued online. primary goal was to introduce guidelines consensus criteria for diagnosis provide a comprehensive update all Schema recommendations....
There is no approved therapy for hepatitis C virus (HCV) infection after kidney transplantation, and data regarding the use of new-generation direct antiviral agents (DAAs) have been published so far. The aims this pilot study were to assess efficacy safety an interferon-free sofosbuvir-based regimen treat chronic HCV in transplant recipients. Twenty-five recipients with given, 12 (n = 19) or 24 weeks 6), sofosbuvir plus ribavirin 3); daclatasvir 4); simeprevir, 1) without 6); ledipasvir,...
Letters25 May 2021Safety and Immunogenicity of Anti–SARS-CoV-2 Messenger RNA Vaccines in Recipients Solid Organ TransplantsFREEOlivier Marion, MD, Arnaud Del Bello, Florence Abravanel, PharmD, PhD, Chloé Couat, MSc, Stanislas Faguer, Laure Esposito, Anne Hebral, Jacques Izopet, Nassim Kamar, PhDOlivier MDToulouse Rangueil University Hospital, Paul Sabatier University, INSERM UMR 1291, Toulouse Institute for Infectious Inflammatory Disease (Infinity), Toulouse, FranceSearch more papers by...
This case series study assesses whether a fourth dose of SARS-CoV-2 messenger RNA (mRNA)–based vaccine is associated with improved anti–SARS-CoV-2 antibody response in solid organ transplant recipients France.
Thrombotic microangiopathy (TMA) is one of the hallmark vascular lesions antiphospholipid syndrome nephropathy (APSN). These are at high risk recurrence after kidney transplantation. The complement pathway thought to be active in this process. We used eculizumab treat three consecutive transplant recipients with posttransplant TMA due APSN that was resistant plasmapheresis and explored deposition apoptotic cell markers on sequential biopsies. Treatment resulted a rapid dramatic improvement...
Although large retrospective studies have identified the presence of donor-specific antibodies (DSAs) to be a risk factor for rejection and impaired survival after liver transplantation, long-term predicted pathogenic potential individual DSAs transplantation remains unclear. We investigated incidence, prevalence consequences in maintenance transplant (LT) recipients. Two hundred sixty-seven LT recipients, who had undergone at least 6 months previously been screened twice using...
Abstract Background Ribavirin is currently recommended for treating chronic hepatitis E virus (HEV) infection. This retrospective European multicenter study aimed to assess the sustained virological response (SVR) in a large cohort of solid organ transplant (SOT) recipients with HEV infection treated ribavirin monotherapy (N = 255), identify predictive factors SVR, and evaluate impact RNA mutations on response. Methods Data from 255 SOT 30 centers were analyzed. was given at median dose 600...
Patients with chronic kidney disease, dialysis patients and transplant are at high risk of developing severe coronavirus disease 2019 (COVID-19). Data regarding the immunogenicity anti-severe acute respiratory syndrome 2 messenger RNA (anti-SARS-CoV-2 mRNA) vaccines in were published recently. We assessed anti-SARS-CoV-2 mRNA vaccine patients.One hundred nine on haemodialysis (n = 85) or peritoneal 24) have received two injections 30-μg doses BNT162b2 COVID-19 (Pfizer-BioNTech) that...
Summary Background and objectives Within the last few years, anti–human leukocyte antigen detection assays have significantly improved. This study asked, using Luminex single-antigen assay, whether an allograft nephrectomy allowed donor-specific alloantibodies to appear that were not previously detected in serum when failed kidney was still place. Design, setting, participants, & measurements After losing stopping immunosuppressive therapy, proportions of nondonor-specific compared...
It is widely accepted that HLA donor-specific antibodies (DSA) are associated with antibody-mediated rejection and graft loss. However, in many transplant programs, preformed anti-HLA-Cw anti-HLA-DP DSA not considered organ allocation policies because their clinical relevance still uncertain.We analyzed the impact of Cw/DP through a retrospective study, comparing 48 patients transplanted isolated (Cw/DP group) (i) 104 matched HLA-sensitized kidney recipients No at D0 (No (ii) 47 A, -B, -DR,...
Little is known about the impact of posttransplant blood transfusion on sensitization anti-HLA antibodies and formation donor-specific (DSAs). The aims our study were to determine 1-year incidence DSAs (assessed using a solid-phase assay) antibody-mediated rejection (AMR) in kidney transplant patients who had or not received during first year after transplantation. Included 390 non-HLA-sensitized an ABO-compatible previously simultaneously nonkidney transplant. Overall, 64% red cell within...
AIMTo investigate the role of tacrolimus intra-patient variability (IPV) in adult liver-transplant recipients. METHODSWe retrospectively assessed a cohort recipients and analyzed its effect on occurrence graft rejection de novo donor-specific antibodies (dn DSAs), as well
Ribavirin is efficient at treating chronic hepatitis E virus infection in solid-organ transplant patients. However, the early kinetics of viral replication under therapy and impact immunosuppressant regimens on are unknown: thus, determining aim our study.Thirty-five patients with a were given ribavirin for 3 months. The (HEV) RNA concentrations determined before treatment, days 7, 15, 21 months 1, 2, during after cessation.A sustained virological response (SVR) occurred 63%. Decreased...
Hepatitis E virus genotype-3 (HEV3) infection can cause chronic hepatitis in immunosuppressed patients and induce extra-hepatic manifestations, such as neurological symptoms, kidney injuries, immune-mediated thrombocytopenia. Very few cases of HEV-induced manifestations have been reported. Herein, we report, for the first time, a case de novo membranoproliferative glomerulonephritis that occurred transplant patient who developed HEV3 infection, which was successfully treated with ribavirin.
ObjectivesMany transplant physicians screen for and treat asymptomatic bacteriuria (ASB) during post-kidney-transplant surveillance. We investigated whether antibiotics are effective in reducing the occurrence of symptomatic urinary tract infection (UTI) kidney recipients with ASB.MethodsWe performed this multicentre, randomized, open-label trial who had ASB were ≥2 months post-transplantation. randomly assigned participants to receive or no therapy. The primary outcome was incidence UTI...
Anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination is recommended in patients who underwent a transplant because of an increased risk developing severe disease 2019 (COVID-19), and mortality.1Caillard S. Anglicheau D. Matignon M. et al.An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 recipients kidney transplants.Kidney Int. 2020; 98: 1549-1558Abstract Full Text PDF PubMed Scopus (197) Google Scholar Because weak...
Our aim was to assess the real-world effectiveness of immune checkpoint inhibitors for treatment patients with progressive multifocal leukoencephalopathy (PML).We conducted a multicenter survey compiling retrospective data from 79 PML patients, including 38 published cases and 41 unpublished cases, who received as add-on standard care. One-year follow-up were analyzed determine clinical outcomes safety profile. Logistic regression used identify variables associated 1-year...